The YYR (YY1- RKIP) Regulatory Axis in the pathogenesis of Cancer and Immune Evasion
William Ung1, Benjamin Bonavida2
1Department of Microbiology, Immunology & Molecular Genetics, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA, 90095, USA.
Background:
The transcription factor Yin Yang 1 (YY1) and the Raf kinase inhibitory protein (RKIP) represent two molecular entities with diametrically opposed roles in cancer biology. They are key modulators of multiple cellular processes, including apoptosis, metastasis, and cell survival. YY1 functions predominantly as an oncogenic driver, promoting tumorigenesis, epithelial-mesenchymal transition (EMT), immune evasion, and resistance to chemo-immuno-therapy. In contrast, RKIP acts as a metastasis suppressor and chemo-immuno-sensitizer, inhibiting critical oncogenic signaling pathways. The inverse correlation between high YY1 and low RKIP expressions has been observed across various malignancies (such as prostate cancer, melanoma, colorectal cancer, cervical cancer, hematologic malignancies, etc.), suggesting a tightly regulated molecular axis influencing tumor progression and therapeutic response. This review systematically examines the contrasting roles of YY1 and RKIP in cancer pathogenesis (e.g. cell proliferation and cell cycle, angiogenesis, immune cells infiltration and immunosuppressive TME, check point inhibitors, resistance to apoptosis, cell energetics, etc.). Based on their opposing activities, we propose the term YYR-the YY1-RKIP regulatory network- to explain the interplay. YYR captures the bidirectional and context-dependent nature of their relationship for understanding transcriptional programming, immune suppression, tumor aggressiveness, and therapeutic resistance in cancer.
Conclusion:
Understanding the dynamics of the YYR axis may offer new insights into prognostic markers and therapeutic strategies aimed at restoring tumor suppressor function and overcoming treatment resistance. Accordingly, we explore potential therapeutic strategies aimed at targeting YYR.
More Related Videos
10:32Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs
Published on: December 19, 2019
11:00Real-Time Quantitative Measurement of Tumor Cell Migration and Invasion Following Synthetic mRNA Transfection
Published on: June 23, 2023
Related Concept Videos
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Abnormal Proliferation
Mechanisms of Retrovirus-induced Cancers
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Negative Regulator Molecules
